Martin K Childers DO
Professor, Rehabilitation Medicine, U of WA Sch of Med
Join to View Full Profile
1959 Ne Pacific StSeattle, WA 98195
Phone+1 206-598-4295
Fax+1 206-598-2813
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Martin Childers, DO is a physiatrist in Seattle, Washington. He is currently licensed to practice medicine in Washington. He is a Professor at U of WA Sch of Med.
Education & Training
University of Missouri-ColumbiaResidency, Physical Medicine and Rehabilitation, 1991 - 1994
College of Osteopathic Medicine of the PacificClass of 1990
Certifications & Licensure
WA State License 2012 - 2025
American Board of Physical Medicine and Rehabilitation Physical Medicine & Rehabilitation
Publications & Presentations
PubMed
- 21 citationsSafety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial.Perry B Shieh, Nancy L Kuntz, James J Dowling, Wolfgang Müller-Felber, Carsten G Bönnemann
The Lancet. Neurology. 2023-12-01 - 21 citationsIncreased tissue stiffness triggers contractile dysfunction and telomere shortening in dystrophic cardiomyocytesAlex C.Y. Chang, Gaspard Pardon, Andrew H. Chang, Haodi Wu, Sang-Ging Ong
Stem Cell Reports. 2021-05-20 - 17 citationsAAV-Mediated Gene Transfer Restores a Normal Muscle Transcriptome in a Canine Model of X-Linked Myotubular Myopathy.Jean-Baptiste Dupont, Jianjun Guo, Edith Renaud-Gabardos, Karine Poulard, Virginie Latournerie
Molecular Therapy. 2020-02-05
Press Mentions
Gene Therapy Leads to Long-Term Benefits in Dog Model of Devastating Childhood DiseaseJune 7th, 2017
Gene Therapy Leads to Robust Improvements in Animal Model of Fatal Muscle DiseaseJanuary 22nd, 2014
Grant Support
- Development of novel genetic medicine approaches to treat orphan diseasesKINEA BIO, INC.2024–2027
